fda import alert 66-80 glp-1 Issues on GLP-1s Following Launch of “Green List” FDA is moving to restrict

Richard J

Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual beta-cell function

That waiver has been extended through December 31, 2025 (fourth extension as of late 2024), allowing providers nationwide to prescribe Schedule II-V medications via telehealth without an initial in-person visit

To that end, the pharma companies have wasted no time firing off cease and desist letters and suing compounders, alleging unfair competitionthat theyre copying their patent-protected products and tricking consumers into thinking theyre getting the same thing

Emotional eaters (depression, anxiety, boredom) reverted toward baseline after a year